Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants

Phase 3

Terminated

Conditions: Healthy Participants

Interventions: Drug: Tbo-filgrastim

First Posted Date: 2017-01-23

Last Posted Date: 2022-12-13

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 1

Registration Number: NCT03029000

Locations: 🇺🇸
Teva Investigational Site 14029, Duarte, California, United States
🇺🇸
Teva Investigational Site 14025, La Jolla, California, United States
🇺🇸
Teva Investigational Site 14023, Beech Grove, Indiana, United States

and more 6 locations

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Propionate/Salmeterol
Drug: Placebo MDPI
Drug: Fluticasone Propionate

First Posted Date: 2016-12-02

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 841

Registration Number: NCT02980133

Locations: 🇺🇸
Teva Investigational Site 13881, Birmingham, Alabama, United States
🇺🇸
Teva Investigational Site 13883, Little Rock, Arkansas, United States
🇺🇸
Teva Investigational Site 13906, Bakersfield, California, United States

and more 115 locations

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Albuterol Sulfate

First Posted Date: 2016-11-21

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 397

Registration Number: NCT02969408

Locations: 🇺🇸
Teva Investigational Site 13964, Litchfield Park, Arizona, United States
🇺🇸
Teva Investigational Site 13959, Bakersfield, California, United States
🇺🇸
Teva Investigational Site 13954, Los Angeles, California, United States

and more 41 locations

A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)

Phase 3

Terminated

Conditions: Chronic Cluster Headache

Interventions: Drug: Fremanezumab
Drug: Placebo

First Posted Date: 2016-11-16

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 259

Registration Number: NCT02964338

Locations: 🇺🇸
Teva Investigational Site 13834, Phoenix, Arizona, United States
🇺🇸
Teva Investigational Site 13819, Canoga Park, California, United States
🇺🇸
Teva Investigational Site 13811, Santa Monica, California, United States

and more 80 locations

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

Phase 3

Terminated

Conditions: Episodic Cluster Headache

Interventions: Drug: Placebo
Drug: Fremanezumab

First Posted Date: 2016-10-26

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 169

Registration Number: NCT02945046

Locations: 🇺🇸
Teva Investigational Site 13834, Phoenix, Arizona, United States
🇺🇸
Teva Investigational Site 13819, Canoga Park, California, United States
🇺🇸
Teva Investigational Site 13811, Santa Monica, California, United States

and more 79 locations

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Phase 4

Terminated

Conditions: Asthma

Interventions: Drug: Fludeoxyglucose F 18 (FDG)
Drug: Reslizumab
Drug: Placebo

First Posted Date: 2016-10-18

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 5

Registration Number: NCT02937168

Locations: 🇺🇸
Teva Investigational Site 13808, New Brunswick, New Jersey, United States

Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

Phase 1

Completed

Conditions: Pregnancy
Contraception

Interventions: Drug: TV-46046 - 400 mg/mL
Drug: TV-46046 - 200 mg/mL

First Posted Date: 2016-06-29

Last Posted Date: 2024-02-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 12

Registration Number: NCT02817464

Locations: 🇺🇸
Teva Investigational Site 001, Philadelphia, Pennsylvania, United States
🇺🇸
Teva Investigational Site 002, Norfolk, Virginia, United States

A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes

Phase 2

Withdrawn

Conditions: Nonalcoholic Steatohepatitis
Type 2 Diabetes Mellitus

Interventions: Drug: TEV-45478
Drug: Placebo

First Posted Date: 2016-05-11

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Registration Number: NCT02769091

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Propionate MDPI
Drug: Fluticasone Propionate/Salmeterol MDPI
Drug: Fluticasone propionate/salmeterol

First Posted Date: 2016-02-11

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 20

Registration Number: NCT02680561

Locations: 🇺🇸
Teva Investigational Site 13679, Huntington Beach, California, United States
🇺🇸
Teva Investigational Site 13678, Raleigh, North Carolina, United States
🇺🇸
Teva Investigational Site 13677, San Antonio, Texas, United States

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: TEV-48125 - 1
Drug: TEV-48125 - 2
Drug: TEV-48125 - 3
Drug: Placebo

First Posted Date: 2016-02-04

Last Posted Date: 2021-12-13

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 64

Registration Number: NCT02673567

Locations: 🇺🇸
Teva Investigational Site 13529, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy